Citations

Showing 10 of 108162 citations.

Management Patterns and Outcomes of Acute Ischemic Stroke Complicating Transcatheter Aortic Valve Replacement
Alkhouli, Mohamad , Harris, Alyssa Hartsell, Hohmann, Samuel F. , Rihal, Charanjit S. , Alqahtani, Fahad, Alkhouli, Mohamad , Alqahtani, Fahad , Harris, Alyssa , Rihal, Charanjit S.

Mayo Clinic

Stroke | February 11, 2021 | Volume: 52 | Issue: 3 | Pages: No page available

10.1161/strokeaha.120.032376 | PMID 33567872 Get It

Faculty Opinions recommendation of The ZSWIM8 ubiquitin ligase mediates target-directed microRNA degradation.
Liu, Qiuying , Hu, Wenqian

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | February 11, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.739025640.793582460 Get It

Faculty Opinions recommendation of A ubiquitin ligase mediates target-directed microRNA decay independently of tailing and trimming.
Liu, Qiuying , Hu, Wenqian

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | February 11, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.739025636.793582477 Get It

Protocol for the Examination of Specimens From Patients With Soft Tissue Tumors of Intermediate Malignant Potential, Malignant Soft Tissue Tumors, and Benign/Locally Aggressive and Malignant Bone Tumors
Fletcher, Christopher D.�M. , Inwards, Carrie Y., Montag, Anthony, Qualman, Stephen J., Krausz, Thomas, Rubin, Brian P. , Peabody, Terrance D. , Rosenberg, Andrew E. , Weiss, Sharon Whelan

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 130 | Issue: 11 | Pages: 1616-1629

10.5858/2006-130-1616-pfteos | PMID 17076523 Get It

Opportunity Knocks: The Pathologist as Laboratory Genetics Consultant
Kant, Jeffrey A., Klein, Roger D.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 130 | Issue: 11 | Pages: 1603-1604

10.5858/2006-130-1603-oktpal | PMID 17076520 Get It

Benefits of Peer Support for Intensive Care Unit Survivors: Sharing Experiences, Care Debriefing, and Altruism
McPeake, Joanne , Iwashyna, Theodore J. , Boehm, Leanne M. , Hibbert, Elizabeth , Bakhru, Rita N. , Bastin, Anthony J. , Butcher, Brad W. , Eaton, Tammy L. , Harris, Wendy, Hope, Aluko A. , Jackson, James C. , Johnson, Annie, Kloos, Janet A. , Korzick, Karen , Meyer, Joel , Montgomery-Yates, Ashley , Slack, Andrew, Wade, Dorothy , Still, Mary, Netzer, Giora, Hopkins, Ramona O., Sevin, Carla M. , Mikkelsen, Mark E. , Quasim, Tara , Haines, Kimberley

Mayo Clinic

American Journal of Critical Care | February 11, 2021 | Volume: 30 | Issue: 2 | Pages: 145-149

10.4037/ajcc2021702 | PMID 33566086 Get It

Background After critical illness, patients are often left with impairments in physical, social, emotional, and cognitive functioning. Peer support interventions have been implemented internationally to ameliorate these issues. Objective To explore what patients believed to be the key mechanisms of effectiveness of peer support programs implemented during critical care recovery. Methods In a secondary analysis of an international qualitative data set, 66 telephone interviews with patients were undertaken across 14 sites in Australia, the United Kingdom, and the United States to understand the effect of peer support during recovery from critical illness. Prevalent themes were documented with framework analysis. Results Most patients who had been involved in peer support programs reported benefit. Patients described 3 primary mechanisms: (1) sharing experiences, (2) care debriefing, and (3) altruism. Conclusion Peer support is a relatively simple intervention that could be implemented to support patients during recovery from critical illness. However, more research is required into how these programs can be implemented in a safe and sustainable way in clinical practice.
Physician variation in the de‐adoption of ineffective statin and fibrate therapy
Everhart, Alexander , Dowd, Bryan , Herrin, Jeph , Higuera, Lucas , Jeffery, Molly M. , Jena, Anupam B. , Shah, Nilay D., Smith, Laura Barrie , Karaca‐Mandic, Pinar , Dowd, Bryan , Herrin, Jeph , Jeffery, Molly Moore , Jena, Anupam B , Karaca-Mandic, Pinar , Everhart, Alexander O , Desai, Nihar R. , Ross, Joseph S.

Mayo Clinic

Health Services Research | February 11, 2021 | Volume: 56 | Issue: 5 | Pages: 919-931

10.1111/1475-6773.13630 | PMID 33569804 Get It

AbstractObjectiveTo describe physicians’ variation in de‐adopting concurrent statin and fibrate therapy for type 2 diabetic patients following a reversal in clinical evidence.Data SourcesWe analyzed 2007‐2015 claims data from OptumLabs® Data Warehouse, a longitudinal, real‐world data asset with de‐identified administrative claims and electronic health record data.Study DesignWe modeled fibrate use among Medicare Advantage and commercially insured type 2 diabetic statin users before and after the publication of the ACCORD lipid trial, which found statins and fibrates were no more effective than statins alone in reducing cardiovascular events among type 2 diabetic patients. We modeled fibrate use trends with physician random effects and physician characteristics such as age and specialty.Data ExtractionWe identified patient‐year‐quarters with one year of continuous insurance enrollment, type 2 diabetes diagnoses, and fibrate use. We designated the physician most responsible for patients’ diabetes care based on evaluation and management visits and prescriptions of glucose‐lowering drugs.Principal FindingsFibrate use increased by 0.12 percentage points per quarter among commercial patients (95% CI, 0.10 to 0.14) and 0.17 percentage points per quarter among Medicare Advantage patients (95% CI, 0.13 to 0.20) before the trial and then decreased by 0.16 percentage points per quarter among commercial patients (95% CI, −0.18 to −0.15) and 0.05 percentage points per quarter among Medicare Advantage patients (95% CI, −0.06 to −0.03) after the trial. However, 45% of physicians treating commercial patients and 48% of physicians treating Medicare Advantage patients had positive trends in prescribing following the trial. Physicians’ characteristics did not explain their variation (pseudo R2 = 0.000).ConclusionOn average, physicians decreased fibrate prescribing following the ACCORD lipid trial. However, many physicians increased prescribing following the trial. Observable physician characteristics did not explain variations in prescribing. Future research should examine whether physicians vary similarly in other de‐adoption settings.
Surgical treatment of primary mobile spine chordoma
Kolz, Joshua M. , Wellings, Elizabeth P. , Houdek, Matthew T. , Yaszemski, Michael J. , Rose, Peter S. , Houdek, Matthew T , Clarke, Michelle J.

Mayo Clinic

Journal of Surgical Oncology | February 11, 2021 | Volume: 123 | Issue: 5 | Pages: 1284-1291

10.1002/jso.26423 | PMID 33567141 Get It

AbstractBackground and ObjectivesChordomas of the mobile spine (C1–L5) are rare malignant tumors. The purpose of this study was to review the outcome of surgical treatment for patients with primary mobile spine chordomas.MethodsThe oncologic outcomes and survival of 26 patients undergoing surgical resection for a primary mobile spine chordoma were assessed over a 25‐year period. The mean follow‐up was 12 ± 6 years.ResultsThe 2‐, 5‐, and 10‐year disease‐free survivals were 95%, 61%, and 55%. The local recurrence‐free survival was improved in patients receiving en bloc resection with negative margins (83% vs. 35%, p = 0.02) and similar in patients receiving adjuvant radiation therapy (43% vs. 45%, p = 0.30) at 10 years. Debulking of the tumor (hazard ratio [HR] = 6.41, p = 0.01) and a local recurrence (HR = 9.52, p = 0.005) were associated with death due to disease. Complications occurred in 19 (73%) patients, leading to reoperation in 9 (35%) patients; this rate was similar in intralesional and en bloc procedures.ConclusionSurgical resection of mobile spine chordomas is associated with a high rate of complications; however, en bloc resection can provide a hope for cure and appears to confer better oncologic outcomes for these tumors without an increase in complications compared to lesser resections.
Use of Artificial Intelligence and Deep Neural Networks in Evaluation of Patients With Electrocardiographically Concealed Long QT Syndrome From the Surface 12-Lead Electrocardiogram
Bos, J. Martijn , Albert, D.J. , Friedman, Paul A. , Ackerman, Michael J. , Bos, Johan M , Attia, Zachi I. , Noseworthy, Peter A.

Mayo Clinic

JAMA Cardiology | February 11, 2021 | Volume: 6 | Issue: 5 | Pages: 532

10.1001/jamacardio.2020.7422 | PMID 33566059 Get It